Why the study?
Cancer is a well-known risk factor for preventable thromboembolic disease, prompting the need for tailored guidance on preventing and managing cancer-associated thrombosis in Saudi Arabia.
This consensus statement provides tailored guidance for the prevention and management of cancer-associated thrombosis in Saudi Arabia, recommending LMWH or DOACs based on patient risk profiles.
Provides Saudi-specific CAT prophylaxis and management guidance; extends international recommendations with regional expert consensus.
Background Cancer is a well-known risk factor of preventable thromboembolic disease. This study aims to provide guidance on the prevention and management of cancer-associated thrombosis (CT) that tailors prophylactic and therapeutic options for medical and surgical oncology patients presenting to health care settings in Saudi Arabia. Methods The present consensus was developed in concordance with the modified Delphi-based approach, which incorporates a face-to-face meeting between two voting rounds to gain experts' feedback on the proposed statements. All experts were either oncologists, hematologists, or hemato-oncologist with an active clinical and research profile in hemato-oncology. Results The experts highlighted that the comparatively high incidence of inherited thrombophilia among the Saudi population may account for a higher CT burden in the Kingdom than in other parts of the world. However, due to the lack of literature that assesses CT in Saudi Arabia, primary venous thromboembolism prophylaxis should be tailored according to a valid risk assessment of cancer patients and should be implemented in routine practice. For hospitalized medical oncology patients, the experts agreed that prophylaxis with low-molecular-weight heparin (LMWH) should be offered, regardless of the presence of acute illness. For ambulatory medical oncology patients, LMWH or direct oral anticoagulants (DOACs) prophylaxis should be offered for high-risk patients. Concerning surgical patients, they agreed that all oncology patients undergoing surgery should be offered thromboprophylaxis. In terms of secondary prophylaxis, the experts recommended continuing a prophylactic dose of anticoagulant (LMWH or DOAC), for an appropriate period depending on the cancer type and stage. Finally, they also provided a set of statements on management of CT in Saudi Arabia. Conclusion The present modified Delphi-based study combined the best available evidence and clinical experience with the current health care policies and settings in Saudi Arabia to build a consensus statement on the epidemiology, prevention, and management of CT.
No takes yet. Share an insight, caveat, or question.
AlSheef et al. (2023) studied Cancer-Associated Thromboembolism (n=8). Consensus guidelines was evaluated on Consensus agreement on statements. A panel of eight Saudi experts developed a consensus statement using a modified Delphi approach to provide tailored guidance on the prophylaxis and management of cancer-associated thrombosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: